Figure 4

IL-10 and CRP pre-treatment of viral expansion cultures downregulates HIV-1C replication in vitro. PHA-activated healthy-donor PBMCs were pre-incubated with recombinant human IL-6 (2.5 ng/ml), IL-10 (5 ng/ml) or CRP (1 μg/ml), for 1 h before infection with a representative R/H phenotype HIV-1C primary isolate, and HIV-1 p24 levels were determined by ELISA after 7 days of culture. Treatments schemes are shown as follows: (1) Mock; (2) recombinant human (rh) IL-10; (3) rh CRP; (4) IL-6+IL-10; anti-IL-10 mAb+IL-10. The data are representative of the results from two independent experiments. Results are shown as mean ± SD of relative p24 antigen production expressed as percent of the mean p24 titer measured in the Mock-treated cultures. * = statistical difference of the medians, p < 0.05; ** = statistical difference of the medians, p < 0.01; (ns) indicates that the p-value of the correlation coefficient was more than .05 (not significant).